Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
Conclusion
In this series, pazopanib showed interesting activity in DSRCT patients who progressed after prior chemotherapy without major toxicity.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Anemia | Bilirubin | Cancer & Oncology | Chemotherapy | Databases & Libraries | Desmoplastic Small Round Cell Tumor (DSRCT) | Diarrhoea | Hypertension | Liver | Sarcomas | Toxicology | Urology & Nephrology